4-Pro-MET vs Psilocybin: Synthetic vs Natural Compared

Both are 4-substituted tryptamine prodrugs that convert to active 4-hydroxy metabolites in the body. That's where the similarities thin out. Psilocybin, found in 200+ mushroom species, is the most clinically studied psychedelic with 15+ active clinical trials. 4-Pro-MET, first available in 2025, has zero clinical data. They differ in origin, legal status, research evidence, subjective character, and practical availability – and this comparison walks through all of it.

Both are prodrugs of 4-hydroxytryptamines, but they yield different active metabolites at the nitrogen position. 4-Pro-MET converts to 4-HO-MET (N-methyl-N-ethyl). Psilocybin converts to psilocin/4-HO-DMT (N,N-dimethyl). One structural difference – asymmetric vs. symmetric N-substitution – and it produces distinct subjective profiles.

Community researchers consistently call the MET-series experience "more visual, less headspace" relative to psilocybin. 4-HO-MET brings sharp geometric visuals, color enhancement with "artificial saturation," and a clear, playful cognitive state where ego function stays intact. Psilocybin/psilocin goes the other direction: organic, flowing visuals with deeper introspection, stronger emotional processing, and more pronounced ego dissolution at higher doses.

Shulgin put it well in TiHKAL – 4-HO-MET was "qualitatively a lot like psilocin" but likely distinguishable in blind testing. A nuanced take that holds up. And the body load? 4-Pro-MET / 4-HO-MET is consistently described as lighter than psilocybin mushrooms, possibly because synthetic compounds lack the other alkaloids present in mushroom preparations.

This is the biggest gap between the two. Psilocybin has been administered to over 2,000 participants across 15+ clinical trials, with established safety profiles, known LD50 values (~280 mg/kg rat oral), and documented therapeutic efficacy for treatment-resistant depression, end-of-life anxiety, and alcohol use disorder. 4-Pro-MET? Zero clinical data. No LD50. No controlled human studies.

That evidence asymmetry can't be overstated. Shared tryptamine pharmacology does suggest some degree of safety profile overlap, but equating the safety of a well-characterized clinical compound with a novel research chemical available for less than a year would be scientifically irresponsible. Full stop.